Trigeminal neuralgia. Syndrome of paroxysmal facial pain Tic douloureux
Conditions
Interventions
Intervention 1: Intervention Group:
Laser treatment with medication
Medication: Tablets 200 mg orally, once a day for three months
Laser:
GaAlAS diode laser with a wavelength of 810 nm, continus form
Treatment - Drugs
Intervention Group:
Laser treatment with medication
Medication: Tablets 200 mg orally, once a day for three months
Laser:
GaAlAS diode laser with a wavelength of 810 nm, continus form, dose 6.36
Control group:
Medication with sham laser
Medication: Carbamazepine, tablets, 200 mg orally, once a day for three months
Laser: Sham laser
Sponsors
Dental Research Center, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with definite diagnosis of TN according to the criteria of the International Headache Society (IHS) were included [HIS 3 with ICD-10 (G44.0) coding]; Patients who were under standard pharmaceutical treatment for TN but had not experienced any improvement were also included. Exclusion criteria: pregnancy Patients
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare the severity of pain. Timepoint: Before treatment - Upon completion of treatment- At two months after completion of treatment. Method of measurement: Visual Analog Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| The side effects of the drug include dizziness. Timepoint: Before treatment- Upon completion of treatment-At two months after completion of treatment. Method of measurement: According patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shamsoulmolouk Najafi
Tehran University of Medical Sciences / School of Dentistry, Tehran University of Medical Sciences I
Outcome results
None listed